{"pmid":32437232,"title":"Viral Induced Genetics Revealed by Multi-Dimensional Precision Medicine Transcriptional Workflow Applicable to COVID-19.","text":["Viral Induced Genetics Revealed by Multi-Dimensional Precision Medicine Transcriptional Workflow Applicable to COVID-19.","Precision medicine requires the translation of basic biological understanding to medical insights, mainly applied to characterization of each unique patient. In many clinical settings, this requires tools that can be broadly used to identify pathology and risks. Patients often present to the intensive care unit with broad phenotypes, including multiple organ dysfunction syndrome (MODS) resulting from infection, trauma, or other disease processes. Etiology and outcomes are unique to individuals, making it difficult to cohort patients with MODS, but presenting a prime target for testing/developing tools for precision medicine. Using multi-time point whole blood (cellular/acellular) total transcriptomics in 27 patients, we highlight the promise of simultaneously mapping viral/bacterial load, cell composition, tissue damage biomarkers, balance between syndromic biology vs. environmental response, and unique biological insights in each patient using a single platform measurement. Integration of a transcriptome workflow yielded unexpected insights into the complex interplay between host genetics and viral/bacterial specific mechanisms, highlighted by a unique case of virally induced genetics (VIG) within one of these 27 patients. The power of RNAseq to study unique patient biology while investigating environmental contributions can be a critical tool moving forward for translational sciences applied to precision medicine.","Physiol Genomics","Prokop, Jeremy W","Shankar, Rama","Gupta, Ruchir","Leimanis, Mara L","Nedveck, Derek","Uhl, Katie","Chen, Bin","Hartog, Nicholas L","Van Veen, Jason","Sisco, Joshua S","Sirpilla, Olivia","Lydic, Todd A","Boville, Brian","Hernandez, Angel","Braunreiter, Chi","Kuk, ChiuYing C","Singh, Varinder","Mills, Joshua","Wegener, Marc","Adams, Marie","Rhodes, Mary","Bachmann, Andre S","Pan, Wenjing","Byrne-Steele, Miranda L","Smith, D Casey","Depinet, Mollye","Brown, Brittany E","Eisenhower, Mary","Han, Jian","Haw, Marcus","Madura, Casey","Sanfilippo, Dominic J","Seaver, Laurie H","Bupp, Caleb","Rajasekaran, Surender","32437232"],"abstract":["Precision medicine requires the translation of basic biological understanding to medical insights, mainly applied to characterization of each unique patient. In many clinical settings, this requires tools that can be broadly used to identify pathology and risks. Patients often present to the intensive care unit with broad phenotypes, including multiple organ dysfunction syndrome (MODS) resulting from infection, trauma, or other disease processes. Etiology and outcomes are unique to individuals, making it difficult to cohort patients with MODS, but presenting a prime target for testing/developing tools for precision medicine. Using multi-time point whole blood (cellular/acellular) total transcriptomics in 27 patients, we highlight the promise of simultaneously mapping viral/bacterial load, cell composition, tissue damage biomarkers, balance between syndromic biology vs. environmental response, and unique biological insights in each patient using a single platform measurement. Integration of a transcriptome workflow yielded unexpected insights into the complex interplay between host genetics and viral/bacterial specific mechanisms, highlighted by a unique case of virally induced genetics (VIG) within one of these 27 patients. The power of RNAseq to study unique patient biology while investigating environmental contributions can be a critical tool moving forward for translational sciences applied to precision medicine."],"journal":"Physiol Genomics","authors":["Prokop, Jeremy W","Shankar, Rama","Gupta, Ruchir","Leimanis, Mara L","Nedveck, Derek","Uhl, Katie","Chen, Bin","Hartog, Nicholas L","Van Veen, Jason","Sisco, Joshua S","Sirpilla, Olivia","Lydic, Todd A","Boville, Brian","Hernandez, Angel","Braunreiter, Chi","Kuk, ChiuYing C","Singh, Varinder","Mills, Joshua","Wegener, Marc","Adams, Marie","Rhodes, Mary","Bachmann, Andre S","Pan, Wenjing","Byrne-Steele, Miranda L","Smith, D Casey","Depinet, Mollye","Brown, Brittany E","Eisenhower, Mary","Han, Jian","Haw, Marcus","Madura, Casey","Sanfilippo, Dominic J","Seaver, Laurie H","Bupp, Caleb","Rajasekaran, Surender"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437232","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1152/physiolgenomics.00045.2020","keywords":["picu","precision medicine","rnaseq","transcriptomics","multiple organ dysfunction syndrome"],"topics":["Mechanism"],"weight":1,"_version_":1667521393860804608,"score":9.490897,"similar":[{"pmid":32391242,"pmcid":"PMC7205603","title":"A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.","text":["A Precision Medicine Approach to SARS-CoV-2 Pandemic Management.","Purpose of review: Precision medicine (PM) represents a new paradigm in disease diagnosis, prevention, and treatment. To apply PM premises in an emerging coronavirus pandemic acquires potentially greater relevance in order to allow the selection of specific preventive measures as well as biomarkers that will be useful in disease management. Recent findings: The identification of the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the responsible for the coronavirus disease 2019 (COVID-19) pandemic had led to a plethora of strategies to contain viral dissemination, affecting life styles and personal behaviors. Viral genomic sequencing has shown that SARS-CoV-2 spike protein utilizes angiotensin-converting enzyme 2 (ACE2) found on ciliated epithelial cells of the human lungs as its specific receptor. Neutralizing antibodies to the receptor-binding domain of the spike protein were detected in patients recovered from COVID-19; however, both T cells and NK cells were reduced in severe cases. Excessive and uncontrolled releases of pro-inflammatory cytokines such as IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor (TNFalpha) were increased in severe patients. These cytokines might be useful biomarkers of disease worsening and potential targets for new biological therapies currently under investigation. Summary: Present knowledge and recent developments in PM approach to COVID-19 disease prevention, evaluation, and management are pointed out. Better understanding of pathogenic pathways together with an accurate phenotype classification of patients presented with SARS-CoV-2 infection and symptoms might contribute to a more accurate definition of biomarkers and other diagnostic tools, which may lead to more precise mitigation strategies, personalized pharmacologic options, as well as new biological therapy developments.","Curr Treat Options Allergy","Crisci, Carlos D","Ardusso, Ledit R F","Mossuz, Antonela","Muller, Leila","32391242"],"abstract":["Purpose of review: Precision medicine (PM) represents a new paradigm in disease diagnosis, prevention, and treatment. To apply PM premises in an emerging coronavirus pandemic acquires potentially greater relevance in order to allow the selection of specific preventive measures as well as biomarkers that will be useful in disease management. Recent findings: The identification of the new coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as the responsible for the coronavirus disease 2019 (COVID-19) pandemic had led to a plethora of strategies to contain viral dissemination, affecting life styles and personal behaviors. Viral genomic sequencing has shown that SARS-CoV-2 spike protein utilizes angiotensin-converting enzyme 2 (ACE2) found on ciliated epithelial cells of the human lungs as its specific receptor. Neutralizing antibodies to the receptor-binding domain of the spike protein were detected in patients recovered from COVID-19; however, both T cells and NK cells were reduced in severe cases. Excessive and uncontrolled releases of pro-inflammatory cytokines such as IL-1B, IL-1RA, IL-7, IL-8, IL-9, IL-10, fibroblast growth factor (FGF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and tumor necrosis factor (TNFalpha) were increased in severe patients. These cytokines might be useful biomarkers of disease worsening and potential targets for new biological therapies currently under investigation. Summary: Present knowledge and recent developments in PM approach to COVID-19 disease prevention, evaluation, and management are pointed out. Better understanding of pathogenic pathways together with an accurate phenotype classification of patients presented with SARS-CoV-2 infection and symptoms might contribute to a more accurate definition of biomarkers and other diagnostic tools, which may lead to more precise mitigation strategies, personalized pharmacologic options, as well as new biological therapy developments."],"journal":"Curr Treat Options Allergy","authors":["Crisci, Carlos D","Ardusso, Ledit R F","Mossuz, Antonela","Muller, Leila"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32391242","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1007/s40521-020-00258-8","keywords":["biomarkers","covid-19","coronavirus management algorithm","precision medicine"],"topics":["Treatment"],"weight":1,"_version_":1666528580099637249,"score":245.67656},{"pmid":32330209,"pmcid":"PMC7107203","title":"A precision medicine approach to managing 2019 novel coronavirus pneumonia.","text":["A precision medicine approach to managing 2019 novel coronavirus pneumonia.","In December 2019, several patients with pneumonia of an unknown cause were detected in Wuhan, China. On 7 January 2020, the causal organism was identified as a new coronavirus, later named as the 2019 novel coronavirus (2019-nCoV). Genome sequencing found the genetic sequence of 2019-nCoV homologous to that of severe acute respiratory syndrome-associated coronavirus. As of 29 January 2020, the virus had been diagnosed in more than 7000 patients in China and 77 patients in other countries. It is reported that both symptomatic and asymptomatic patients with 2019-nCoV can play a role in disease transmission via airborne and contact. This finding has caused a great concern about the prevention of illness spread. The clinical features of the infection are not specific and are often indistinguishable from those of other respiratory infections, making it difficult to diagnose. Given that the virus has a strong ability to spread between individuals, it is of top priority to identify potential or suspected patients as soon as possible-or the virus may cause a serious pandemic. Therefore, a precision medicine approach to managing this disease is urgently needed for detecting and controlling the spread of the virus. In this article, we present such an approach to managing 2019-nCoV-related pneumonia based on the unique traits of the virus recently revealed and on our experience with coronaviruses at West China Hospital in Chengdu, China.","Precis Clin Med","Wang, Minjin","Zhou, Yanbing","Zong, Zhiyong","Liang, Zongan","Cao, Yu","Tang, Hong","Song, Bin","Huang, Zixing","Kang, Yan","Feng, Ping","Ying, Binwu","Li, Weimin","32330209"],"abstract":["In December 2019, several patients with pneumonia of an unknown cause were detected in Wuhan, China. On 7 January 2020, the causal organism was identified as a new coronavirus, later named as the 2019 novel coronavirus (2019-nCoV). Genome sequencing found the genetic sequence of 2019-nCoV homologous to that of severe acute respiratory syndrome-associated coronavirus. As of 29 January 2020, the virus had been diagnosed in more than 7000 patients in China and 77 patients in other countries. It is reported that both symptomatic and asymptomatic patients with 2019-nCoV can play a role in disease transmission via airborne and contact. This finding has caused a great concern about the prevention of illness spread. The clinical features of the infection are not specific and are often indistinguishable from those of other respiratory infections, making it difficult to diagnose. Given that the virus has a strong ability to spread between individuals, it is of top priority to identify potential or suspected patients as soon as possible-or the virus may cause a serious pandemic. Therefore, a precision medicine approach to managing this disease is urgently needed for detecting and controlling the spread of the virus. In this article, we present such an approach to managing 2019-nCoV-related pneumonia based on the unique traits of the virus recently revealed and on our experience with coronaviruses at West China Hospital in Chengdu, China."],"journal":"Precis Clin Med","authors":["Wang, Minjin","Zhou, Yanbing","Zong, Zhiyong","Liang, Zongan","Cao, Yu","Tang, Hong","Song, Bin","Huang, Zixing","Kang, Yan","Feng, Ping","Ying, Binwu","Li, Weimin"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330209","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1093/pcmedi/pbaa002","keywords":["2019-ncov","covid-19","mers","sars","coronavirus pneumonia","epidemic","pandemic","precision medicine"],"locations":["Wuhan","China","China","Chengdu","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1666138494551982081,"score":194.546},{"pmid":32426374,"pmcid":"PMC7203508","title":"Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.","text":["Cardiovascular Impairment in COVID-19: Learning From Current Options for Cardiovascular Anti-Inflammatory Therapy.","In December 2019, Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2, occurred in China and has currently led to a global pandemic. In addition to respiratory involvement, COVID-19 was also associated with significant multiple organ dysfunction syndrome (MODS). Cardiovascular impairment has been observed and is now drawing growing attention. Cardiovascular protective strategies are urgent and of great significance to the overall prognosis of COVID-19 patients. Direct viral infection, cytokine storm, and aggravation of existing cardiovascular diseases were recognized as possible mechanisms of cardiovascular impairment in COVID-19. Hyperactivated inflammation plays an important role in all three mechanisms and is considered to be fundamental in the development of cardiovascular impairment and MODS in COVID-19. Therefore, in addition to conventional cardiovascular treatment, anti-inflammatory therapy is a reasonable strategy for severe cases to further enhance cardiovascular protection and potentially mitigate MODS. We reviewed the inflammatory features and current promising treatments of COVID-19 as well as cardiovascular anti-inflammatory therapies that have been verified in previous clinical trials with positive outcomes. We believe that targeting the central pathway (IL-1beta, TNF-alpha, IL-6), balancing the Th1 and Th2 response, and administering long-term anti-inflammatory therapy might be promising prospects to reduce cardiovascular impairment and even MODS during the acute and recovery phases of COVID-19. The cardiovascular anti-inflammatory therapies might be of great application value to the management of COVID-19 patients and we further propose an algorithm for the selection of anti-inflammatory therapy for COVID-19 patients with or at high risk of cardiovascular impairment. We recommend to take the experiences in cardiovascular anti-inflammatory therapy as references in the management of COVID-19 and conduct related clinical trials, while the clinical translation of novel treatments from preclinical studies or in vitro drug screening should proceed with caution due to unguaranteed efficacy and safety profiles.","Front Cardiovasc Med","Wang, Lun","Zhang, Yang","Zhang, Shuyang","32426374"],"abstract":["In December 2019, Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2, occurred in China and has currently led to a global pandemic. In addition to respiratory involvement, COVID-19 was also associated with significant multiple organ dysfunction syndrome (MODS). Cardiovascular impairment has been observed and is now drawing growing attention. Cardiovascular protective strategies are urgent and of great significance to the overall prognosis of COVID-19 patients. Direct viral infection, cytokine storm, and aggravation of existing cardiovascular diseases were recognized as possible mechanisms of cardiovascular impairment in COVID-19. Hyperactivated inflammation plays an important role in all three mechanisms and is considered to be fundamental in the development of cardiovascular impairment and MODS in COVID-19. Therefore, in addition to conventional cardiovascular treatment, anti-inflammatory therapy is a reasonable strategy for severe cases to further enhance cardiovascular protection and potentially mitigate MODS. We reviewed the inflammatory features and current promising treatments of COVID-19 as well as cardiovascular anti-inflammatory therapies that have been verified in previous clinical trials with positive outcomes. We believe that targeting the central pathway (IL-1beta, TNF-alpha, IL-6), balancing the Th1 and Th2 response, and administering long-term anti-inflammatory therapy might be promising prospects to reduce cardiovascular impairment and even MODS during the acute and recovery phases of COVID-19. The cardiovascular anti-inflammatory therapies might be of great application value to the management of COVID-19 patients and we further propose an algorithm for the selection of anti-inflammatory therapy for COVID-19 patients with or at high risk of cardiovascular impairment. We recommend to take the experiences in cardiovascular anti-inflammatory therapy as references in the management of COVID-19 and conduct related clinical trials, while the clinical translation of novel treatments from preclinical studies or in vitro drug screening should proceed with caution due to unguaranteed efficacy and safety profiles."],"journal":"Front Cardiovasc Med","authors":["Wang, Lun","Zhang, Yang","Zhang, Shuyang"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426374","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3389/fcvm.2020.00078","keywords":["coronavirus disease 2019","cardiovascular anti-inflammatory therapy","cardiovascular diseases","cardiovascular impairment","inflammation"],"locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728780668928,"score":163.2383},{"pmid":32397688,"title":"SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions.","text":["SARS-CoV-2/COVID-19: Viral Genomics, Epidemiology, Vaccines, and Therapeutic Interventions.","The COVID-19 pandemic is due to infection caused by the novel SARS-CoV-2 virus that impacts the lower respiratory tract. The spectrum of symptoms ranges from asymptomatic infections to mild respiratory symptoms to the lethal form of COVID-19 which is associated with severe pneumonia, acute respiratory distress, and fatality. To address this global crisis, up-to-date information on viral genomics and transcriptomics is crucial for understanding the origins and global dispersion of the virus, providing insights into viral pathogenicity, transmission, and epidemiology, and enabling strategies for therapeutic interventions, drug discovery, and vaccine development. Therefore, this review provides a comprehensive overview of COVID-19 epidemiology, genomic etiology, findings from recent transcriptomic map analysis, viral-human protein interactions, molecular diagnostics, and the current status of vaccine and novel therapeutic intervention development. Moreover, we provide an extensive list of resources that will help the scientific community access numerous types of databases related to SARS-CoV-2 OMICs and approaches to therapeutics related to COVID-19 treatment.","Viruses","Uddin, Mohammed","Mustafa, Farah","Rizvi, Tahir A","Loney, Tom","Suwaidi, Hanan Al","Al-Marzouqi, Ahmed H Hassan","Eldin, Afaf Kamal","Alsabeeha, Nabeel","Adrian, Thomas E","Stefanini, Cesare","Nowotny, Norbert","Alsheikh-Ali, Alawi","Senok, Abiola C","32397688"],"abstract":["The COVID-19 pandemic is due to infection caused by the novel SARS-CoV-2 virus that impacts the lower respiratory tract. The spectrum of symptoms ranges from asymptomatic infections to mild respiratory symptoms to the lethal form of COVID-19 which is associated with severe pneumonia, acute respiratory distress, and fatality. To address this global crisis, up-to-date information on viral genomics and transcriptomics is crucial for understanding the origins and global dispersion of the virus, providing insights into viral pathogenicity, transmission, and epidemiology, and enabling strategies for therapeutic interventions, drug discovery, and vaccine development. Therefore, this review provides a comprehensive overview of COVID-19 epidemiology, genomic etiology, findings from recent transcriptomic map analysis, viral-human protein interactions, molecular diagnostics, and the current status of vaccine and novel therapeutic intervention development. Moreover, we provide an extensive list of resources that will help the scientific community access numerous types of databases related to SARS-CoV-2 OMICs and approaches to therapeutics related to COVID-19 treatment."],"journal":"Viruses","authors":["Uddin, Mohammed","Mustafa, Farah","Rizvi, Tahir A","Loney, Tom","Suwaidi, Hanan Al","Al-Marzouqi, Ahmed H Hassan","Eldin, Afaf Kamal","Alsabeeha, Nabeel","Adrian, Thomas E","Stefanini, Cesare","Nowotny, Norbert","Alsheikh-Ali, Alawi","Senok, Abiola C"],"date":"2020-05-14T11:00:00Z","year":2020,"_id":"32397688","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3390/v12050526","keywords":["covid-19","sars-cov-2","coronavirus","pandemic","viral genomics"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666714494705860608,"score":148.00609},{"pmid":32376402,"title":"Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies.","text":["Transcriptional landscape of SARS-CoV-2 infection dismantles pathogenic pathways activated by the virus, proposes unique sex-specific differences and predicts tailored therapeutic strategies.","The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics are yet available to control disease evolution, more in-depth understanding of the pathogenic mechanisms induced by SARS-CoV-2 will help to characterize new targets for the management of COVID-19. The present study identified a specific set of biological pathways altered in primary human lung epithelium upon SARS-CoV-2 infection, and a comparison with SARS-CoV from the 2003 pandemic was studied. The transcriptomic profiles were also exploited as possible novel therapeutic targets, and anti-signature perturbation analysis predicted potential drugs to control disease progression. Among them, Mitogen-activated protein kinase kinase (MEK), serine-threonine kinase (AKT), mammalian target of rapamycin (mTOR) and I kappa B Kinase (IKK) inhibitors emerged as candidate drugs. Finally, sex-specific differences that may underlie the higher COVID-19 mortality in men are proposed.","Autoimmun Rev","Fagone, Paolo","Ciurleo, Rosella","Lombardo, Salvo Danilo","Iacobello, Carmelo","Palermo, Concetta Ilenia","Shoenfeld, Yehuda","Bendtzen, Klaus","Bramanti, Placido","Nicoletti, Ferdinando","32376402"],"abstract":["The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) has posed a serious threat to global health. As no specific therapeutics are yet available to control disease evolution, more in-depth understanding of the pathogenic mechanisms induced by SARS-CoV-2 will help to characterize new targets for the management of COVID-19. The present study identified a specific set of biological pathways altered in primary human lung epithelium upon SARS-CoV-2 infection, and a comparison with SARS-CoV from the 2003 pandemic was studied. The transcriptomic profiles were also exploited as possible novel therapeutic targets, and anti-signature perturbation analysis predicted potential drugs to control disease progression. Among them, Mitogen-activated protein kinase kinase (MEK), serine-threonine kinase (AKT), mammalian target of rapamycin (mTOR) and I kappa B Kinase (IKK) inhibitors emerged as candidate drugs. Finally, sex-specific differences that may underlie the higher COVID-19 mortality in men are proposed."],"journal":"Autoimmun Rev","authors":["Fagone, Paolo","Ciurleo, Rosella","Lombardo, Salvo Danilo","Iacobello, Carmelo","Palermo, Concetta Ilenia","Shoenfeld, Yehuda","Bendtzen, Klaus","Bramanti, Placido","Nicoletti, Ferdinando"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32376402","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.autrev.2020.102571","keywords":["bioinformatics","covid-19","coronavirus","pathogenesis","sars","sars-cov-2"],"locations":["rapamycin"],"e_drugs":["Serine"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666597097367928833,"score":133.35712}]}